Pages: [1]   Go Down
Author Topic: VNS Featured at American Epilepsy Society Meeting  (Read 3606 times)
0 Members and 1 Guest are viewing this topic.
Head Cheese
Hero Member

Karma: +9/-1
Offline Offline

Posts: 7791

Head Cheese

« on: December 03, 2004, 03:40:52 AM »


VNS Therapy™ Featured in 25 Presentations Including Data Confirming VNS Therapy Safety in Younger Patient Population and Highlighted in Special Panel on Neurostimulation

HOUSTON, Dec. 3 /PRNewswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX - News) announced today that Vagus Nerve Stimulation (VNS) Therapy will be featured in 25 presentations at the annual American Epilepsy Society (AES) Meeting, taking place December 3 through 8 in New Orleans, LA. Expert neurologists from leading medical institutions, including Cornell University, Cleveland Clinic, UCLA, Rush University Medical Center, University of Texas-Houston and New York University Medical Center, will present results of their respective VNS Therapy studies. VNS Therapy, the only FDA-approved device to treat epilepsy, is delivered from a small implantable generator that delivers mild pulses to the left vagus nerve in the neck. VNS Therapy, an adjunctive therapy used to reduce the frequency of seizures in adults and adolescents over 12 years of age with partial onset seizures that are refractory to antiepileptic medications, has been used to treat more than 28,000 patients worldwide.
Several of the presentations discuss VNS Therapy in the younger patient population. Leading physicians will present data on early versus late introduction of VNS Therapy, vagus nerve stimulation in pharmacoresistant epilepsy patients and therapeutic outcomes of vagus nerve stimulation in intractable epilepsy, all within the younger patient population.

"Studies and growing clinical use have shown that VNS Therapy is a safe and effective treatment option for pharmacoresistant epilepsy patients. In addition to seizure control -- the number one goal in treating epilepsy patients -- many VNS patients are also benefiting from improved cognitive function including increased alertness, concentration and mood," said Dr. Prakash Kotagal, pediatric epileptologist at Cleveland Clinic Foundation who is presenting a study on vagus nerve stimulation in pre-adolescent children with pharmacoresistant epilepsy at AES. "The added quality of life benefits of VNS Therapy are especially important when treating a pediatric population."

On December 4 at 12:45 p.m., a special panel will discuss "Neurostimulation 2004: A Safety Update." Led by Douglas R. Labar, M.D., Ph.D. of the Comprehensive Epilepsy Center, New York Presbyterian-Weill Cornell Medical Center, and James W. Wheless, M.D. of the Texas Comprehensive Epilepsy Program at the University of Texas, Houston, this special panel of physicians and industry experts including Reese S. Terry, Jr., founder of Cyberonics, will discuss the latest trends in neurostimulation: safety, efficacy, patient identification, mechanism of action, current and future applications of neurostimulation.

"Clinicians and researchers must stay up-to-date on the latest devices and procedures as neurostimulation becomes more widely used for epilepsy as well as other neurological disorders," said Dr. Wheless. "We hope that by participating in an exchange with panelists of diverse and varying perspectives, attendees will be better equipped to incorporate neurostimulation therapies into their practice as appropriate."

In addition, neurologists and psychiatrists will participate in a roundtable discussion on the prevalence of mood disorders in patients with epilepsy.

"If you are going through hell, keep going." (Sir Winston Churchill, 1874-1965)
VNS implanted Sept 02, turned off Dec 04, Generator ex-planted Nov 07
Electrodes are in me for LIFE!
Pages: [1]   Go Up
Jump to: